Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.gov public full text Public Domain

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

NewLink Genetics Corporation · 2006
ClinicalTrials.gov · Datasets · License: Public Domain · 2006
Open Source ↗
breast-cancercancercolon-cancerendometrial-cancerlung-cancermelanomaneoplasmsnon-small-cell-lung-cancer
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. CRLX101 is designed to increase the exposure of tumor cells to CPT while minimizing side effects. OBJECTIVES: • Determine the safety, toxicity, and the maximum tolerated dose (MTD) of CRLX101 when administered intravenously to subjects with advanced solid tumors.
Conceptio Open Archive

Analyze & explore related research in Conceptio

Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.

This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 1410416
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive